West Haven, Connecticut 06516

  • Nicotine


The dose-effect curve to estimate a threshold delivery rate for reinforcement. The project addresses the FDA Center for Tobacco Products (CTP) interest #1: Nicotine dependence threshold among youth and adults and impact of nicotine reduction on tobacco product use behavior (e.g., topography, compensation, switching, multiple use, initiation, cessation and relapse). IV nicotine, in contrast to ECs, can deliver precise, reproducible dosing, which is necessary for accurately assessing dose-response and threshold effects. The estimated threshold for reinforcement will establish a benchmark for evaluating the addictive potential of ECs and other inhaled nicotine products.

Study summary:

A placebo-controlled study that will recruit male and female nicotine dependent smokers/EC users (n=18) to complete four separate experimental sessions. Each session will include one randomly assigned infusion that will be either saline or a single dose of nicotine (1 mg per 70 kg body weight) delivered at three different infusion rates, rapid, moderate or slow (0.24, 0.048 or 0.024 mcg per kg body weight per second). A total infusion duration of 10 min will be maintained during each session by adding saline infusions of variable duration after nicotine delivery. This will be achieved by two separate infusion pumps, one for saline and one for nicotine. For example, the rapid 0.24 mcg/kg/s condition will include a 1 min infusion of nicotine followed by a 9 min infusion of saline. The subjects will be blinded to the infusion pump procedures. The rapid delivery rate, which we have used in our prior studies, induces positive subjective drug effects and suppresses symptoms of nicotine withdrawal. The moderate delivery rate,0.048 mcg/kg/s, approximates the rate of nicotine intake encountered while smoking a typical cigarette over 5 min (4). The slowest nicotine delivery rate, 0.024mcg/kg/s, was chosen to approximate the rate of nicotine intake encountered while using a newer EC (5).


Inclusion Criteria: 1. Female and male smokers that smoke ≥ 5 cigarettes per day for the past year 2. aged 18 to 30 years 3. urine cotinine levels > 100 ng/mL consistent with nicotine intake of an active smoker (23) 4. not seeking treatment at the time of the study for nicotine dependence 5. in good health as verified by medical history, screening examination, and screening laboratory tests 6. for women, not pregnant as determined by pregnancy screening, nor breast feeding, and using acceptable birth control methods. Exclusion Criteria: 1. history of major medical or psychiatric disorders that the physician investigator deems as contraindicated for the subject to be in the study 2. regular use of psychotropic medication (antidepressants, antipsychotics, or anxiolytics) 3. current alcohol or substance dependence for any other recreational or prescription drugs other than nicotine 4. urine drug screening indicating recent illicit drugs use (with the exception of marijuana).



Primary Contact:

Principal Investigator
Kevin Jensen, Ph.D.
Yale University

Lance Barnes
Phone: 203-937-4823
Email: lance.barnes@yale.edu

Backup Contact:


Location Contact:

West Haven, Connecticut 06516
United States

Mehmet Sofuoglu, M.D.,Ph.D.
Phone: 203-937-4809
Email: mehmet.sofuoglu@yale.edu

Site Status: Recruiting

Data Source: ClinicalTrials.gov

Date Processed: September 27, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.